Tadalafil
Product Images NDC 50436-7001

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50436-7001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504367001)

Tadalafil 2.5 mg tablets packaging label from Unit Dose Services. The label shows the product name, strength (2.5 mg), and quantity (30 tablets). It indicates each tablet contains 2.5 mg of tadalafil and advises not to split tablets, with the entire dose to be taken. Manufacturer information is included as Eli Lilly and Company, Indianapolis, IN, with lot and expiration date placeholders. The label also contains storage warnings and an NDC number.*

FDA Label Image

Label Image (Lbl504367010)

Tadalafil 5 mg tablets label by Unit Dose Services. The label indicates prescription use only with one tablet per unit dose pouch and 200 pouches per case. It provides storage instructions, manufacturer details including Eli Lilly and Company, and repackager information for Unit Dose Services, LLC. The label includes contact information for questions and a barcode at the bottom.*

FDA Label Image

Structural Formula (Tadalafil Uspi 01)

Chemical structure diagram of tadalafil, showing its molecular framework including fused rings and functional groups.*

FDA Label Image

Figure 1 (Tadalafil Uspi 02)

A set of four line graphs depicting the difference in blood pressure measurements between Tadalafil and placebo over time. The charts show standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure differences in mmHg across multiple time points up to 96 hours. Each plot tracks changes with error bars indicating variability.*

FDA Label Image

Figure 2 (Tadalafil Uspi 03)

Two line graphs depict the effects on standing and supine systolic blood pressure over 24 hours post-dose. The graphs compare Tadalafil 20 mg combined with doxazosin 8 mg (solid line) and placebo with doxazosin 8 mg (dotted line). The vertical axis shows systolic BP changes in mmHg; the horizontal axis shows time in hours after dosing.*

FDA Label Image

Figure 3 (Tadalafil Uspi 04)

A line graph showing systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo combined with doxazosin at 8:00 or 20:00. The graph compares four groups: 20 mg tadalafil at 08:00, placebo at 08:00, 20 mg tadalafil at 20:00, and placebo at 20:00, all with 8 mg once-daily doxazosin at 08:00, plotting systolic BP changes over time.*

FDA Label Image

Figure 4 (Tadalafil Uspi 05)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three different dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The graph depicts concentration changes and includes error bars.*

FDA Label Image

Figure 5 (Tadalafil Uspi 06)

A line graph comparing the change from baseline in IIEF total score over a 12-week treatment period for Tadalafil 5 mg versus placebo. The x-axis shows duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change from baseline in IIEF total score, with Tadalafil 5 mg showing a greater decrease compared to placebo. Statistical significance is noted at p<0.01.*

FDA Label Image

Figure 6 (Tadalafil Uspi 07)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period comparing Tadalafil 5 mg and placebo. The y-axis represents the change in score, and the x-axis shows duration in weeks. Tadalafil shows a greater decrease in score compared to placebo, with statistical significance indicated at one time point.*

FDA Label Image

Figure 7 (Tadalafil Uspi 08)

A line graph showing the least squares mean change from baseline in weeks of therapy up to 26 weeks. It compares the effects of Tadalafil/Finasteride and Placebo/Finasteride on a scale with decreasing values. The graph includes statistical significance markers (a for p<0.001, b for p<0.05) for differences between groups at certain time points.*

FDA Label Image

Figure 8 (Tadalafil Uspi 09)

A line graph comparing the change from baseline in IIEF total score over a 12-week duration for Tadalafil 5 mg versus placebo. The graph shows data points at multiple weeks, indicating a greater decrease in score for Tadalafil compared to placebo, with statistical significance noted at p<0.01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.